Physician profile
Stephen Wallace
NPI 1144255498
$929.81
in general payments reported to CMS, 2019-2025
20 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $44.88 · 2024: $32.09 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $240 · Food and Beverage: $32.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $240.00 |
| Food and Beverage | $32.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $240.00 | 2025 | Truelok |
| E.R. Squibb & Sons, L.L.C. | $123.88 | 2019 | |
| Amgen INC. | $77.92 | 2019-2020 | |
| Janssen Biotech, INC. | $76.99 | 2019 | |
| Genentech USA, INC. | $58.77 | 2019-2024 | Perjeta, Phesgo |
| Takeda Pharmaceuticals U.S.A., INC. | $51.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.24 | 2019 | |
| Pfizer INC. | $42.38 | 2019-2020 | |
| Genzyme Corporation | $28.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.63 | 2019 | |
| Gilead Sciences, INC. | $27.48 | 2019 | |
| Seagen INC. | $26.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.22 | 2024 | Onpattro |
| Merck Sharp & Dohme LLC | $14.54 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.47 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.09 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.49 | 2019 | |
| Foundation Medicine, INC. | $12.48 | 2019 | |
| Abbvie INC. | $12.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.